Full Year 2025 Clinuvel Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Clinuvel Pharmaceuticals Ltd (CLVLF) reported a 10% increase in revenues, surpassing the $100 million mark with $105 million in total.
- The company achieved a ninth consecutive annual profit and declared an eighth consecutive annual dividend, with the fourth being fully franked.
- There was a 22% increase in cash reserves, enhancing the company's financial stability and enabling exploration of new opportunities.
- The company has expanded its presence in the US with 104 trained and accredited sites, aiming for 120 by the end of the year.
- Clinuvel Pharmaceuticals Ltd (CLVLF) remains debt-free for the 20th consecutive year, providing a strong financial buffer for future R&D programs.
- Expenses increased by 20%, primarily due to reinvestment in business expansion and R&D programs.
- Personnel costs rose by 31% due to hiring and upskilling, impacting overall expenditure.
- Some revenue recognition was delayed due to sales orders not being delivered by the end of June, affecting the current financial period's results.
- The expansion of SCENESSE for adolescent EPP patients faced a setback with the EMA not fully supporting the expansion.
- The company anticipates regulatory review delays, with FDA reviews taking longer than the standard nine months due to manpower shortages.
(audio in progress) I will now hand over to Malcolm Bull, Head of Investor Relations and Australian Operations to conduct the proceedings.
Thank you for the introduction, Stella, and also thanks to Monsoon Communications, who are facilitating yet another investor webinar for us. It's pleasing we have more than 190 participants on the line from around the world, and we thank you for your interest in CLINUVEL. I will say that some shareholders have told us they prefer shorter 30 minute type webinar. But we have extended today's webinar at the request of several institutions to 45 minutes. And that reflects the number of questions that we've received as well.
So our webinar will be in three parts. The first part is to discuss the financial and operating results of the 2025 financial year, as Stella mentioned with Managing Director, Dr. Philippe Wolgen; and Chief Financial Officer,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
